M.D. Anderson Cancer Center: Lymphoma trials

The registry lists 172 Lymphoma studies with M.D. Anderson Cancer Center as lead sponsor. 9 are open to participants now and 84 have results posted.

Early Phase 1 5Phase 1 52Phase 2 108Phase 3 7Phase 4 2No phase 21(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic LymphomaRecruitingNCT07513129Phase 1
• A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone LymphomaRecruitingNCT06563505Phase 2
• Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.RecruitingNCT06218602Phase 2
• A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone LymphomaRecruitingNCT05929612Phase 2
• A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell LymphomasRecruitingNCT05773040Phase 1
• Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in TexasRecruitingNCT05676450Not applicable
• A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell TherapyRecruitingNCT05464719Phase 2
• Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic MalignanciesRecruitingNCT05011045
• Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell TherapyRecruitingNCT04870853
• Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) LymphomaCompletedNCT04465162Phase 2Results posted
• Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell LymphomaCompletedNCT04432506Phase 2Results posted
• Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT04047797Phase 2Results posted
• Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell TransplantationTerminatedNCT03856216Phase 2Results posted
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
• Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03041636Phase 2Results posted
• Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT03019640Phase 2Results posted
• Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular LymphomaCompletedNCT02871219Phase 2Results posted
• Phase II Study of TAK228 in Relapsed LymphomaTerminatedNCT02727777Phase 1/2Results posted
• Smart Start: A Phase II Study of Rituximab, Lenalidomide, and IbrutinibCompletedNCT02636322Phase 2Results posted
• Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC SubtypeTerminatedNCT02589145Phase 1/2Results posted
• Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone LymphomaCompletedNCT02532257Phase 2Results posted
• A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell LymphomaCompletedNCT02529852Phase 1/2Results posted
• Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter TransformationCompletedNCT02420912Phase 2Results posted
• Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT02420795Phase 1/2Results posted
• Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaTerminatedNCT02419469Phase 2Results posted
• Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell LymphomaTerminatedNCT02272686Phase 2Results posted
• Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT02225275Phase 2Results posted
• Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02199184Phase 2Results posted
• Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)TerminatedNCT02169505Phase 2Results posted
• A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT02042950Phase 2Results posted
• Aza-SAHA-GBM With AutoSCT for Refractory LymphomaCompletedNCT01983969Phase 1/2Results posted
• Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid MalignanciesCompletedNCT01919619Phase 2Results posted
• Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node ImagingCompletedNCT01815333Not applicableResults posted
• Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT01701986Phase 1/2Results posted
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
• Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for LymphomaCompletedNCT01538472Phase 1/2Results posted
• Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma PatientsCompletedNCT01520519Phase 2Results posted
• Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)CompletedNCT01490723Phase 2Results posted
• A Study of the HSP90 Inhibitor AUY922TerminatedNCT01485536Phase 2Results posted
• Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT01363128Phase 2Results posted
• Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's LymphomasCompletedNCT01329900Phase 2Results posted
• Stage I/II Nasal NK Cell LymphomaTerminatedNCT01321008Phase 1/2Results posted
• Ofatumumab for Minimal Residual Disease (MRD) and Maintenance TherapyTerminatedNCT01258933Phase 2Results posted
• Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)TerminatedNCT01253460Phase 2Results posted
• Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin LymphomaCompletedNCT01169636Phase 1/2Results posted
• Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation ChemotherapyCompletedNCT01099202Not applicableResults posted
• Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01002755Phase 2Results posted
• Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT00990249Phase 2Results posted
• Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.CompletedNCT00967369Phase 2Results posted
• Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory LymphomaCompletedNCT00967044Phase 1/2Results posted
• Study of Bortezomib in Combination With Cyclophosphamide and RituximabCompletedNCT00958256Phase 2Results posted
• Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular LymphomaCompletedNCT00904722Phase 2Results posted
• Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular LymphomaTerminatedNCT00901927Phase 2Results posted
• Acupuncture for Chemo-Induced Peripheral NeuropathyCompletedNCT00891618Phase 2Results posted
• Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic LymphomaCompletedNCT00866749Phase 2Results posted
• Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's LymphomaTerminatedNCT00810576Phase 2Results posted
• SAHA + CHOP in Untreated T-cell Non-Hodgkin's LymphomaCompletedNCT00787527Phase 1/2Results posted
• Methadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerTerminatedNCT00726830Not applicableResults posted
• Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin LymphomaCompletedNCT00695786Phase 2Results posted
• Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/LymphomaCompletedNCT00669877Phase 2Results posted
• Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin LymphomaCompletedNCT00654732Phase 2Results posted
• Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma PatientsCompletedNCT00651755Not applicableResults posted
• Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell TransplantationCompletedNCT00591630Phase 2Results posted
• Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma PatientsCompletedNCT00577993Phase 3Results posted
• Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid MalignanciesCompletedNCT00536978Phase 2Results posted
• Non-Myeloablative Allogeneic Stem Cell TransplantationCompletedNCT00525876Not applicableResults posted
• Allogeneic Transplantation in Patients With Cutaneous T-Cell LymphomaCompletedNCT00506129Phase 2Results posted
• Autologous and Allogenic Transplantation With Campath-1H for T-Cell LymphomaTerminatedNCT00505921Phase 2Results posted
• Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)TerminatedNCT00500240Phase 3Results posted
• G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL PatientsCompletedNCT00499343Phase 2Results posted
• Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and RituxanCompletedNCT00496873Phase 2Results posted
• Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent LymphomasCompletedNCT00493467Phase 2Results posted
• Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent LymphomasTerminatedNCT00493454Phase 2Results posted
• Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell LymphomaCompletedNCT00477412Phase 1/2Results posted
• Thymoglobulin and Total Lymphoid Irradiation for Hematologic MalignanciesCompletedNCT00476229Not applicableResults posted
• Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid MalignanciesCompletedNCT00472056Phase 2Results posted
• A Study of Actonel for the Prevention of Bone LossCompletedNCT00452439Phase 3Results posted
• Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple MyelomaCompletedNCT00427765Phase 2Results posted
• Cellular Therapy With Cord Blood CellsCompletedNCT00427557Phase 2Results posted
• Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia PatientsCompletedNCT00412243Phase 1/2Results posted
• Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell LymphomaCompletedNCT00411086Phase 2Results posted
• Radioimmunotherapy With 90Y Zevalin for Orbital LymphomaCompletedNCT00387023Not applicableResults posted
• Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)CompletedNCT00364286Phase 2Results posted
• Effect of Zoledronic Acid on Chemotherapy Induced Bone LossCompletedNCT00352846Phase 3Results posted
• Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's LymphomaCompletedNCT00299182Phase 1/2Results posted
• Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell LymphomaCompletedNCT00294632Phase 1/2Results posted
• Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular LymphomaCompletedNCT00290511Phase 2Results posted
• Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or YoungerCompletedNCT00290498Phase 2Results posted
• Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell LymphomaCompletedNCT00290433Phase 2Results posted
• Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell LymphomaCompletedNCT00101010Phase 2Results posted
• Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00081861Phase 2Results posted
• Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid MalignanciesCompletedNCT00048737Phase 1/2Results posted
• Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant DiseasesCompletedNCT00038857Phase 2Results posted
• Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 TherapyActive, not recruitingNCT06049134Phase 4
• An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell LymphomaWithdrawnNCT05929716Phase 2
• A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular LymphomaActive, not recruitingNCT05683171Phase 1/2
• A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell LymphomaActive, not recruitingNCT05495464Early Phase 1
• Feasibility of Combined Genomics/Transcriptomics for Patients With LymphomaActive, not recruitingNCT05464823Not applicable
• Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA StudyWithdrawnNCT05169151
• Nutrition and Physical Activity Intervention in Preventing Excess Weight Gain in Pediatric Patients With Leukemia or Lymphoma Treated With Prednisone and/or DexamethasoneCompletedNCT05049785Early Phase 1